BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bitzan M, Hammad RM, Bonnefoy A, Al Dhaheri WS, Vézina C, Rivard GÉ. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade. Pediatr Nephrol 2018;33:1437-42. [PMID: 29728803 DOI: 10.1007/s00467-018-3957-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang XY, Yang RC. [Advances in the treatment of thrombotic thrombocytopenic purpura]. Zhonghua Xue Ye Xue Za Zhi 2019;40:1055-9. [PMID: 32023744 DOI: 10.3760/cma.j.issn.0253-2727.2019.12.020] [Reference Citation Analysis]
2 Barnum SR, Bubeck D, Schein TN. Soluble Membrane Attack Complex: Biochemistry and Immunobiology. Front Immunol 2020;11:585108. [PMID: 33240274 DOI: 10.3389/fimmu.2020.585108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Lingwood C. Verotoxin Receptor-Based Pathology and Therapies. Front Cell Infect Microbiol 2020;10:123. [PMID: 32296648 DOI: 10.3389/fcimb.2020.00123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]